They are not a measure of liver function. A badly scarred liver can return normal enzymes, because there are fewer cells left to leak.
ALT and AST are enzymes that live inside liver cells. When a cell is damaged, they leak into the blood. So the test measures leakage, not performance — a liver can be badly scarred and doing its job poorly while the enzymes sit in the normal range, because there are fewer cells left to leak.
Actual liver function is better read from albumin, bilirubin and clotting. The enzymes tell you something is irritating the liver now.
ALT is the more liver‑specific of the two. AST is also abundant in heart and skeletal muscle, so a raised AST can come from a hard workout, a muscle injury or a statin‑related muscle problem rather than the liver at all.
That is why our baseline includes ALT and not AST. It is ₡12,000, and adding AST would have added another ₡12,000 to answer a question ALT mostly answers. AST goes on when the ratio between them matters.
Where both are available, their relationship carries information:
Both are patterns, not tests. Plenty of people do not read the textbook, and the ratio has been shifted by anything that raises AST from muscle.
The list is longer than most people expect, which is why a mildly raised ALT is a reason to look further rather than to panic:
Because of the exercise effect, an unexpected result after a hard week of training is worth repeating before it is investigated.
Laboratory reference ranges for ALT were set from populations that, it turns out, included a great many people with undiagnosed fatty liver. Several groups have argued that the true healthy upper limit is meaningfully lower than most laboratories report, and that the thresholds should differ between men and women.
This has been debated for years without being settled into universal practice, and ranges still vary between laboratories. The practical consequence: an ALT at the top of the stated range is not automatically fine, particularly alongside central weight, raised triglycerides and a high HbA1c. Read as a group, those four describe one picture.
Fatty liver is common, usually silent, and sits directly on the path the rest of the panel is measuring. It is also the one thing on the baseline that can be improved substantially without any medicine at all, which makes it worth knowing about early.
And it matters for safety. Several of the medicines used in metabolic care are processed by the liver, and a baseline before starting is the only way to know later whether a change is the drug or the disease.
One mildly raised enzyme is a prompt for a conversation and often a repeat — not a diagnosis and not a reason for a liver supplement. What it means depends on how high, what else is on the panel, what you take and what you drink, which is a discussion with a physician.
Every patient starts the same way: thirty minutes with a physician, then a full biomarker panel drawn at a laboratory near you. Whether any medicine follows is your doctor’s decision, made after reading your results with you.
Measure my biomarkers